Clinical trials · Minneapolis–St. Paul, MN
Interstitial Lung Disease clinical trials in Minneapolis–St. Paul
We’re tracking 11 recruiting interstitial lung disease studies with a site in or near Minneapolis–St. Paul — including Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Minneapolis–St. Paul
- NCT06129240Recruiting
Study of a new inhaled treprostinil powder for PH-ILD
This study tests a new dry powder inhaled medicine called LIQ861 for people with pulmonary hypertension related to lung scarring (PH-ILD). If you are already taking an inhaled treprostinil treatment but need better control, this trial may help you switch to a potentially easier-to-use version.
Minneapolis, MinnesotaAges 18–80 - NCT07366034RecruitingPhase 3
Testing nerandomilast for children with lung scarring
This trial tests a new oral medicine, nerandomilast, to see if it helps children and teens (ages 2 to under 18) who have a type of lung disease that causes scarring (interstitial lung disease). The study monitors how well patients tolerate the drug and whether it improves their breathing.
Minneapolis, MinnesotaAges 2–17 - NCT07201922RecruitingPhase 3
Can a new pill help slow lung changes in people with family risk?
This trial tests a new drug called nerandomilast to see if it can slow down early lung changes in people who have a close family member with a type of lung scarring called pulmonary fibrosis. You may join if you are 40 or older, have a parent, sibling, or child with this condition, and have early signs of lung changes on a CT scan.
Minneapolis, MinnesotaAges 40 years+ - NCT06911632Recruiting
AI-assisted check for pulmonary hypertension in interstitial lung disease
This study uses an AI tool to help doctors decide if you should be tested for pulmonary hypertension (high blood pressure in the lungs), which can be a complication of interstitial lung disease. If the tool suggests you might have it, you may get an echocardiogram (an ultrasound of the heart) and a right heart catheterization (a test to measure pressure in the heart) to find out for sure.
Minneapolis, MinnesotaAges 18 years+ - NCT06806592RecruitingPhase 3
Testing nerandomilast for lung scarring from rheumatic disease
This study tests a new medicine called nerandomilast to see if it can help people with lung scarring caused by autoimmune rheumatic diseases like rheumatoid arthritis or scleroderma. The goal is to slow down lung damage and improve breathing.
Minneapolis, MinnesotaAges 18 years+ - NCT04905693Enrolling by invitationPhase 3
Extension inhaled treprostinil study for fibrotic lung disease
This is an add-on (extension) study testing whether continuing inhaled treprostinil can help people with fibrotic lung disease who took part in earlier related studies. It mainly continues treatment and follow-up for eligible participants.
Minneapolis, MinnesotaAges 40 years+ - NCT06751069Recruiting
Home exercise and coaching for lung scarring
This study tests a home-based exercise and health coaching program for people with scarring in their lungs (fibrotic ILD). The goal is to see if doing rehab at home, with support from a coach, can help you feel better and breathe easier.
Minneapolis, MinnesotaAges 18 years+ - NCT01915511Recruiting
Long-term registry for new or worsening lung scarring
This study collects health information over time from people with newly diagnosed idiopathic pulmonary fibrosis (IPF) or other lung scarring diseases that are getting worse. It’s meant to better understand disease patterns and outcomes, which may help doctors plan future care.
Minneapolis, MinnesotaAges 21 years+ - NCT05943535RecruitingPhase 3
Breathing treprostinil to slow progressive lung scarring
This Phase 3 trial tests whether inhaled treprostinil can slow progression of lung fibrosis (scarring) that keeps getting worse despite standard care. It also looks at safety, because inhaled medicine can cause side effects and needs careful monitoring.
Minneapolis, MinnesotaAges 18 years+ - NCT07155187RecruitingPhase 2/Phase 3
Study of telisotuzumab adizutecan for EGFR-mutated lung cancer
This trial tests a new drug, telisotuzumab adizutecan (given through a vein), alone or with another targeted therapy, versus standard treatments for people with a specific type of advanced lung cancer that has an EGFR mutation and has gotten worse after previous treatment.
Saint Louis Park, MinnesotaAges 18 years+ - NCT07365241RecruitingPhase 3
Study of ABBV-706 vs standard care for advanced small cell lung cancer
This trial tests a new drug called ABBV-706 against standard treatments (topotecan, lurbinectedin, or amrubicin) for people with small cell lung cancer that has come back or stopped responding to previous therapies. The goal is to see if ABBV-706 works better at controlling the cancer.
Edina, MinnesotaAges 18 years+
Hear when a new Interstitial Lung Disease trial opens near Minneapolis–St. Paul, MN
We’ll email you when one opens near Minneapolis–St. Paul, MN — at most once a week, no account needed, unsubscribe anytime.
Interstitial Lung Disease trials in other cities
Where these studies are running near Minneapolis–St. Paul
Institutions with a site for the recruiting interstitial lung disease studies listed above.
- University of Minnesota · 8 studies
- HealthPartners Frauenshuh Cancer Center
- Minnesota Oncology - Edina Clinic /ID# 280698
- University of Minnesota Masonic Children's Hospital
What taking part in a interstitial lung disease study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting interstitial lung disease studies in Minnesota.
Common questions
- Are there interstitial lung disease clinical trials near Minneapolis–St. Paul?
- Yes. We're currently tracking 11 recruiting interstitial lung disease studies with a site near Minneapolis–St. Paul, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a interstitial lung disease study near Minneapolis–St. Paul?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Minneapolis–St. Paul to take part?
- Not necessarily. These studies have a site near Minneapolis–St. Paul, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a interstitial lung disease trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New interstitial lung disease studies open near Minneapolis–St. Paul regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.